After barely growing in 2024, biopharma employment in Massachusetts dropped 3.1% last year. R&D jobs dipped even more, by 3.9%. Biomanufacturing, however, went up.

Original title: “Massachusetts biopharma jobs, including R&D positions, fell in 2025: Report”

While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.

Original title: “Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency”

The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.

Original title: “Cellares, a cell therapy manufacturing specialist, to lay off 100 employees”

Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.

Original title: “Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug”

AI is changing how HCPs seek answers. Pharma marketers need a new strategy.

Original title: “Pharma marketers need a share-of-answer strategy before AI spend”

The National Cancer Institute (NCI) seeks research co- development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.

Original title: “Government Owned Invention Available for License: T Cell Receptors Targeting HPV 6 or HPV 11”

Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.

Original title: “Shareholder pressures Capricor; Lilly dives deeper into vaccines”

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Original title: “How cost and perception could reshape the GLP-1 market”

As a result, CDMOs specializing in orphan drugs are experiencing increased demand for flexible and compliant manufacturing solutions tailored to rare disease therapies. See also Virtual Clinical Trials (VCTs) Market-With the Best Scope, Trends, Benefits, Opportunities to 2030 Global Orphan Drugs CDMO Market Outlook The global orphan drugs CDMO market is projected to witness healthy double-digit growth through 2031, driven by the increasing emphasis on rare disease treatment and supportive regulatory frameworks across major economies. Globalization of Healthcare and Market Accessibility The globalization of healthcare services has improved patient access to rare disease treatments across regions. Emerging markets are increasingly participating in clinical trials and adopting orphan drugs, expanding the global footprint of the market. Orphan drugs CDMOs play a crucial role in addressing these challenges by providing end-to-end services including formulation development, analytical testing, process optimization, clinical trial material manufacturing, scale-up, and commercial production. Their expertise enables drug developers to navigate complex manufacturing requirements while maintaining regulatory compliance and cost efficiency. Rising Focus on Rare Diseases and Unmet Medical Needs The growing orphan drugs CDMO market is closely tied to the increasing recognition of unmet medical needs associated with rare diseases. The presence of established CDMOs and strong R&D infrastructure further strengthens the region’s leadership position. Meanwhile, the Asia-Pacific region is expected to witness rapid growth during the forecast period due to rising awareness of rare diseases, increasing clinical trial activity, and growing adoption of orphan drugs.

Original title: “Orphan Drugs CDMO Market: Growth, Opportunities, Key Players & Forecast Outlook 2031 - SAT PRWire”